Fremanezumab治疗偏头痛合并重性抑郁障碍的UNITE随机临床试验
UNITE试验为双盲、安慰剂对照、平行组随机临床试验,纳入353例偏头痛合并重性抑郁障碍成人患者,评估fremanezumab的疗效与安全性。结果显示,fremanezumab较安慰剂显著减少每月偏头痛天数并改善抑郁症状,安全性与其他fremanezumab试验一致。
要点
- Fremanezumab显著减少偏头痛合并抑郁患者的每月偏头痛天数。
- Fremanezumab还显著改善抑郁症状(HAM-D17评分)。
- 安全性与既往fremanezumab试验一致,未见新安全性问题。
核心结论
- 与安慰剂相比,fremanezumab治疗显著减少每月偏头痛天数并改善抑郁症状。
- 未观察到新的安全性问题。
研究设计与样本
- UNITE研究为双盲、安慰剂对照、平行组随机临床试验,包含4周筛选期、12周双盲期和12周开放标签延伸期。
- 试验在12个国家55个中心开展,于2020年7月9日至2022年8月31日进行。
- 纳入成人发作性偏头痛或慢性偏头痛患者,筛查前符合DSM-5重性抑郁障碍诊断标准至少12个月,且筛查时PHQ-9评分≥10分。
- 共筛查540例患者,353例随机分配至fremanezumab组(n=175)或安慰剂组(n=178)。
- 患者平均(SD)年龄42.9(12.3)岁,女性310例(88%),发作性偏头痛占48%,慢性偏头痛占52%。
主要发现
- 12周双盲期内,每月偏头痛天数较基线的平均(SE)变化:fremanezumab组为-5.1(0.50;95% CI,-6.09至-4.13),安慰剂组为-2.9(0.49;95% CI,-3.89至-1.96),P<.001。
- 第8周时,HAM-D17评分较基线的平均(SE)变化:fremanezumab组为-6.0(0.55;95% CI,-7.10至-4.95),安慰剂组为-4.6(0.54;95% CI,-5.66至-3.55);最小二乘均值(SE)差异为-1.4(0.61;95% CI,-2.61至-0.22;P=.02)。
- 不良事件与其他fremanezumab试验一致。
- 结果在开放标签延伸期内维持。
关键数值与推荐
- 主要终点为12周双盲期内每月偏头痛天数较基线的平均变化。
- 抑郁症状评估采用汉密尔顿抑郁量表17项(HAM-D17)。
- 双盲期给药方案为每月fremanezumab 225 mg或匹配安慰剂;开放标签延伸期所有患者接受每季度fremanezumab 675 mg。
临床怎么用
- 对于偏头痛合并重性抑郁障碍且抑郁症状活跃(PHQ-9≥10)的成人患者,fremanezumab可同时改善偏头痛和抑郁症状。
- 治疗期间安全性与其他fremanezumab试验一致,无需特殊监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Migraine and major depressive disorder are frequently comorbid; however, evidence evaluating the efficacy of preventive migraine therapy in patients with both diseases is limited. OBJECTIVE: To evaluate the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder. DESIGN, SETTING, AND PARTICIPANTS: The UNITE study was a double-blind, placebo-controlled, parallel-group, randomized clinical trial consisting of a 4-week screening period, 12-week double-blind period, and 12-week open-label extension (OLE), conducted between July 9, 2020, and August 31, 2022. The trial was conducted at 55 centers across 12 countries. Eligible patients were adults with episodic migraine (EM) or chronic migraine (CM), history of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for 12 or more months before screening, and active symptoms of depression (9-item Patient Health Questionnaire score of 10 or more) at screening. INTERVENTIONS: Patients were randomized 1:1 to receive monthly fremanezumab (225 mg) or matched placebo. All patients in the OLE received quarterly fremanezumab (675 mg). MAIN OUTCOMES AND MEASURES: The primary end point was the mean change from baseline in monthly migraine days during the 12-week double-blind period. RESULTS: Of the 540 patients screened for the study, 353 patients (mean [SD] age, 42.9 [12.3] years; 310 female [88%]; EM, 48%; CM, 52%) were eligible and randomized to receive fremanezumab (n = 175) or placebo (n = 178). Mean (SE) change from baseline in monthly migraine days during the 12-week double-blind period was -5.1 (0.50; 95% CI, -6.09 to -4.13) for fremanezumab and -2.9 (0.49; 95% CI, -3.89 to -1.96) for placebo (P <.001). Mean (SE) change from baseline in the Hamilton Depression Rating Scale-17 Items score at week 8 was -6.0 (0.55; 95% CI, -7.10 to -4.95) for fremanezumab and -4.6 (0.54; 95% CI, -5.66 to -3.55) for placebo (least squares mean [SE] difference: -1.4 [0.61]; 95% CI, -2.61 to -0.22; P = .02). Adverse events were consistent with other fremanezumab trials. Results were maintained throughout the OLE. CONCLUSIONS AND RELEVANCE: Treatment with fremanezumab compared with placebo resulted in significant reductions in monthly migraine days and depressive symptoms. No new safety concerns were observed. To the authors' knowledge, this was the first placebo-controlled, randomized clinical trial, specifically designed to assess patients with migraine and comorbid depressive disorder, to demonstrate significant improvements in migraine and depressive symptoms with a single pharmacological intervention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04041284.
引用
- Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, et al. Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder: The UNITE Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40323613. doi:10.1001/jamaneurol.2025.0806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。